DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-22 are pending. Claims 5 and 12-22 are rejected. Claims 1 and 6 are objected to. Claims 2-4 and 7-11 are allowed.
Priority
This application is a 35 U.S.C. 371 National Stage Filing of International Application No. PCT/US2023/066748, filed 05/08/2023, which claims priority under 35 U.S.C. 119(a-d) to PRO 63/341,908, filed 05/13/2022. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.
Information Disclosure Statement
The information disclosure statement (IDS) dated 11/12/2024 has been considered.
Claim Objections
Claims 1, 6, 13-15, 17 and 19 objected to because of the following informalities:
Each of the cited claims is objected to for being written in improper Markush format. See MPEP 2173.05(h). Applicant may make the following changes:
Claim 1, in the definition of RN, add “and” between the last two items;
Claim 1, in the definition of RO, add “and” between the last two items;
Claim 5, in the definitions of x and y, add “and” between 3 and 4;
Claim 5, in the definition of R2, add “and” between the last two items;
Claim 5, in the definition of R3, add “and” between the last two items;
Claim 5, in the definition of R2 and R3, add “and” between the last two items;
Claim 5, in the definition of R4, add “and” between the last two items;
Claim 5, in the definition of R3 and R4, add “and” between the last two items;
Claim 12, add “and” between “genetic disorder” and “cardiological disease”;
Claim 13, add “and” between the last two items;
Claim 14, add “and” between the last two items;
Claim 15, add “and” between the last two items;
Claim 17, add “and” between the last two items; and
Claim 19, add “and” between the last two items.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(a)
The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 12-22 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for inhibiting PTPN2, does not reasonably provide enablement for treatment of cancer and other diseases or disorders in general. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention as claimed. Accordingly, the method of claims 12-22 are not enabled.
Nature of the invention:
The invention is drawn to a method of treating a disease or disorder comprising administration of a compound of Formula (I),
PNG
media_image1.png
173
276
media_image1.png
Greyscale
, as recited in instant claim 1.
Breadth of the invention:
The scope of the claimed invention is very broad, as it is drawn to administration of any of the numerous compounds encompassed by Formula (I) as instantly recited to treat a disease or disorder selected from cancer, rheumatic disease, inflammatory disease, immune disease, metabolic disease or disorder, infectious disease, neurodegenerative disease, genetic disorder and cardiological disease.
State of the prior art and predictability in the art:
No compound has ever been found to treat cancer, rheumatic disease, inflammatory disease, immune disease, metabolic disease or disorder, infectious disease, neurodegenerative disease, genetic disorder, or cardiological disease as recited in claim 12 generally. Since this assertion is contrary to what is known in medicine, proof must be provided that this revolutionary assertion has merits. As it relates to cancer, for instance, the existence of such a “silver bullet” is contrary to our present understanding of oncology. The state of the art is not indicative of any pharmaceutical agents that are useful in the treatment of cancer generally. At Page 1004, Cecil Textbook of Medicine states that “each specific type has unique biologic and clinical features that must be appreciated for proper diagnosis, treatment and study”. Different types of cancers affect different organs and have different methods of growth and harm to the body. Also see In re Buting, 163 USPQ 689 (CCPA 1969), wherein ‘evidence involving a single compound and two types of cancer, was held insufficient to establish the utility of the claims directed to disparate types of cancers’. Thus, it is beyond the skill of oncologists today to get an agent to be effective against cancers generally.
A similar statement appears at In re Application of Hozumi et. al., 226 USPQ 353: “In spite of the vast expenditure of human and capital resources in recent years, no one drug has been found which is effective in treating all types of cancer. Cancer is not a simple disease, nor is it even a single disease, but a complex of a multitude of different entities, each behaving in a different way”. There are compounds that treat a modest range of cancers, but no one has ever been able to figure out how to get a compound to be effective against cancer generally, or even a majority of cancers.
The attempts to find compounds to prevent or treat various cancers arguably constitute the single most massive enterprise in all of pharmacology. This has not resulted in finding any treatment for tumors generally. This is because it is now understood that there is no “master switch” for cancers generally; cancers arise from a bewildering variety of differing mechanisms. Even the most broadly effective antitumor agents are only effective against a small fraction of the vast number of different cancers known. This is true in part because cancers arise from a wide variety of sources, primarily a wide variety of failures of the body’s cell growth regulatory mechanisms, but also such external factors such as viruses (an estimated at least 20% are of viral origin e.g. Human papillomavirus, EBV, Hepatitis B and C, HHV-8, HTLV-1 and other retroviruses, and quite possibly Merkel cell polyomavirus, and there is some evidence that CMV is a causative agent in glioblastoma), exposure to chemicals such as tobacco tars, excess alcohol consumption (which causes hepatic cirrhosis, an important cause of HCC), ionizing radiation, and unknown environmental factors.
Similarly, In re Novak, 134 USPQ 335, 337-338 says “unless one with ordinary skill in the art would accept those allegations as obviously valid and correct, it is proper for the examiner to ask for evidence which substantiates them.” There is no such evidence in this case for a compound that treats all types of cancer. Likewise, In re Cartright, 49 USPQ2d 1464, states: “Moreover, we have not been shown that one of ordinary skill would necessarily conclude from the information expressly disclosed by the written description that the active ingredient” does what the specification surmises that it does. That is exactly the case here. Moreover, even if Applicant’s assertion that cancer in general could be treated with these compounds were plausible -- which it is not --, that “plausible” would not suffice, as was stated in Rasmusson v. SmithKline Beecham Corp., 75 USPQ2d 1297, 1301: “If mere plausibility were the test for enablement under section 112, applicants could obtain patent rights to “inventions” consisting of little more than respectable guesses as to the likelihood of their success.
It is commonly known in the pharmaceutical arts that shape dictates function wherein drugs which have a shape complimentary to the protein target will bind and have an effect (this is often referred to simplistically as a “Lock and Key” model). Given the varied shape of protein targets in cancer, it is pure fantasy to speculate that a single drug with a single three-dimensional shape will bind all protein targets implicated in cancer therapy and have an effect in treating all forms of the disease. As such, at present the “silver bullet” drug therapy to treat all forms of cancer is elusive and such a therapy is not recognized in the art where the reality is that different forms of cancer require different drug therapies.
Regarding PTPN1/PTPN2 inhibitors specifically, Farney et al. in WO 2021/127499 A1 disclose a method for inhibiting PTPN2 and/or PTPN1 using compounds of Formula 1 for instance:
PNG
media_image2.png
320
519
media_image2.png
Greyscale
. See top of page 3.
There do not appear to be examples in the prior art of PTPN1/PTPN2 inhibitors that are able to prevent and/or treat all disease or disorders, or even all cancers. Farney et al. for instance, teach that compounds 124,
PNG
media_image3.png
103
334
media_image3.png
Greyscale
(see page 85), and 182,
PNG
media_image4.png
92
334
media_image4.png
Greyscale
(see page 88), were effective in treating colorectal cancer in an in vivo study using mice implanted with MC-38 cells. See page 438, Example 296, as well as Table 6 on page 441.
Level of ordinary skill in the art:
An ordinary artisan in the area of drug development would have experience in synthesizing chemical compounds for particular activities. The synthesis of new drug candidates, while complex, is routine in the art. The process of finding new drugs that have in vitro activity against a particular biological target (i.e., receptor, enzyme, etc.) is well known. Additionally, while high throughput screening assays can be employed, developing a therapeutic method, as claimed, prior to synthesizing and testing compounds is generally not well-known or routine, given the complexity of certain biological systems.
The amount of direction provided and working examples:
Applicant demonstrates PTPN2 inhibition using at least the 7 compounds listed in Example A on pages 106 and 107. Table B on pages 107 and 108 demonstrates growth inhibition of B16F10 mouse melanoma cells by 14 compounds Formula (I).
No examples have been provided that would enable the instantly disclosed compounds for treating the broad range of diseases and disorders listed in claim 12, the rheumatic diseases of claim 13, the inflammatory disease of claim 14, the immune disease of claim 15, the cancers, aside from melanoma, of claim 16, the metabolic disease or disorder of claim 17, the infectious disease of claim 18, the genetic disorder of claim 19, or the cardiological disease of claim 20.
Quantity of experimentation needed to use the invention
The quantity of experimentation needed is undue experimentation. A person having ordinary skill in the art would need not only to identify and/or develop metrics to be able to investigate the efficacy of the disclosed compounds in the treatment of diseases and disorders broadly, but would also need to evaluate the disclosed compounds, with no assurance of success.
The Applicant has not sufficiently disclosed examples demonstrating the efficacy of the instantly claimed compounds in treating diseases and disorders broadly. The utility thereof would not have been readily recognized by a person having ordinary skill in the art at the time of filing, as distinct diseases and disorders have mutually exclusive etiologies. The examples disclosed in the application are not sufficient to overcome the unpredictability of treating diseases and disorders broadly.
A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.
Genentech Inc. V Novo Nordisk A/S (CAFC) 42 USPQ 2d 1001 states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”. Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person having ordinary skill in the art would have to engage in undue experimentation to determine the efficacy of disclosed compounds in treating diseases and disorders broadly, with no assurance of success.
Applicant may amend claim 12, for example, as follows: “A method of treating a PTPN1- or PTPN2-related disease or disorder…”.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claim 5 is rejected under 35 U.S.C. 112(b) being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claim 5 recites a compound of Formula (I-I-C) or (I-I-D) which both include the variable R8. There is insufficient antecedent basis for this limitation in the claim as the term R8 is not defined in the claim itself nor in parent claim 1. Based on the definition wherein R2 and R3 together form a ring in claim 1, it appears as though R8 should instead be R5.
Allowable Subject Matter
Claims 1-22 are free of the prior art.
The closest prior art is from Gallatin et al. in WO 2019/046778 A1. Gallatin et al. teach compounds of formula X with the intended use of cancer immunotherapy, including compound 228 on page 99:
PNG
media_image5.png
80
535
media_image5.png
Greyscale
. Compound 228 is nearly embraced by instant formula (I) of claim 1,
PNG
media_image1.png
173
276
media_image1.png
Greyscale
, except at least wherein the prior art does not have the fluorine and alkoxy groups required on the benzene ring of the instant claims. The instantly claimed compounds are therefore not anticipated by the prior art compounds given the differences indicated above. Further, there is no suggestion or motivation that it would have been obvious to a skilled artisan to modify the referenced compound in such a way as to identify the presently claimed compounds and expect the compounds to inhibit PTPN1/PTPN2 or treat a disease or disorder of the instant claims.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jalisa H. Ferguson whose telephone number is (703)756-1489. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/J.H.F./Examiner, Art Unit 1626
/KAMAL A SAEED/Primary Examiner, Art Unit 1626